Potential Indications of Dupilumab in Th-2 Inflammatory Disease

Proietti Ilaria; Skroza Nevena; Tolino Ersilia; Bernardini Nicoletta; Federica Trovato; Marco Di Fraia; Dybala Agniezska; Potenza Concetta

doi:10.2174/0115748871263396231121060901

Potential Indications of Dupilumab in Th-2 Inflammatory Disease

Rev Recent Clin Trials. 2023 Dec 20. doi: 10.2174/0115748871263396231121060901. Online ahead of print.

Authors

Proietti Ilaria¹, Skroza Nevena¹, Tolino Ersilia¹, Bernardini Nicoletta¹, Federica Trovato¹, Marco Di Fraia¹, Dybala Agniezska¹, Potenza Concetta¹

Affiliation

¹ Unit of Dermatology, Department of Medical-Surgical Science and Biotechnologies, Sapienza University of Rome, A. Fiorini Hospital, Terracina, Latina, Italy.

PMID: 38141197
DOI: 10.2174/0115748871263396231121060901

Abstract

Dupilumab is a fully humanized IgG4 monoclonal antibody, inhibiting IL-4 and IL-13 signaling, which are the main cytokines involved in type 2 inflammatory diseases. Its introduction was a breakthrough in the treatment of moderate-to-severe atopic dermatitis, but it is also used in other inflammatory diseases, including asthma, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis. Recent advances in the understanding of inflammatory pathways have revealed that Th2-type inflammation is involved in a wider range of diseases than previously thought. The aim of our review is to examine off-label therapeutic indications of dupilumab, including bullous dermatoses (pemphigus, bullous pemphigoid) and alopecia areata, and to investigate its potential applications in cancer patients on anti-PD1 therapy.

Keywords: alopecia areata; atopic dermatitis; bullous disease; dupilumab; inflammatory disease; th2.